Corrupt practices cost healthcare $23 billion - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Corrupt practices cost healthcare $23 billion

Pharmaceutical Technology Europe

Fraud and abuse in healthcare costs individual governments as much as $23 billion a year, according to estimates from the World Health Organization (WHO). In a fact sheet on its website, the WHO explains that corruption occurs throughout all stages of the medicines chain, from R&D to dispensing and promotion, and results in the loss of enormous amounts of public health resources. An estimated 10–25% of public procurement spending, including on pharmaceuticals, is lost to corruption. In developing countries, however, up to 89% leakage of procurement and operational costs has been observed.

"Unethical practices along the chain can take many forms such a falsification of evidence, mismanagement of conflict of interest or bribery," says the fact sheet. Examples include conducting clinical trials without regulatory approval, selecting a non-essential medicine for the essential medicines list and promoting the excessive use of medicine to increase profits.

Although some cases are highlighted by the media and regulatory authorities, many unethical practices go unreported. "This is due to fear of victimization and retaliation towards whistle-blowers, and a lack of incentives to come forward," says the fact sheet. "Some forms of corruption have become institutionalized to the point where people feel powerless to influence change in their countries."

According to the WHO, countries with weak governance within the medicines chain are more susceptible to being exploited by corruption as they lack appropriate medicines regulation, enforcement mechanisms and conflict of interest management. Countries with a higher incidence of corruption also have higher child mortality rates, even after statistically controlling the quality for healthcare provision.

To reduce corruption, the WHO believes that thorough checks are required at each step of the medicines chain. "Good governance, transparency, accountability, promoting institutional integrity and moral leadership are also essential," explains the fact sheet.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here